Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Basic): 2017-2024

Historic EPS (Basic) for Apellis Pharmaceuticals (APLS) over the last 8 years, with Dec 2024 value amounting to -$1.60.

  • Apellis Pharmaceuticals' EPS (Basic) rose 471.74% to $1.71 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.35, marking a year-over-year increase of 117.33%. This contributed to the annual value of -$1.60 for FY2024, which is 64.04% up from last year.
  • Apellis Pharmaceuticals' EPS (Basic) amounted to -$1.60 in FY2024, which was up 64.04% from -$4.45 recorded in FY2023.
  • Apellis Pharmaceuticals' EPS (Basic)'s 5-year high stood at -$1.60 during FY2024, with a 5-year trough of -$8.84 in FY2021.
  • In the last 3 years, Apellis Pharmaceuticals' EPS (Basic) had a median value of -$4.45 in 2023 and averaged -$4.07.
  • Its EPS (Basic) has fluctuated over the past 5 years, first slumped by 92.59% in 2021, then spiked by 64.04% in 2024.
  • Apellis Pharmaceuticals' EPS (Basic) (Yearly) stood at -$4.59 in 2020, then crashed by 92.59% to -$8.84 in 2021, then skyrocketed by 30.43% to -$6.15 in 2022, then increased by 27.64% to -$4.45 in 2023, then skyrocketed by 64.04% to -$1.60 in 2024.